Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Blood
Vivek L PatelJames B Bussel

Abstract

Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet responses without continued dosing are limited. Whereas complete responses (CRs) to B-cell depletion in ITP usually last for 1 year in adults, partial responses (PRs) are less durable. Comparable data do not exist for children and 5-year outcomes are unavailable. Patients with ITP treated with rituximab who achieved CRs and PRs (platelets > 150 × 10(9)/L or 50-150 × 10(9)/L, respectively) were selected to be assessed for duration of their response; 72 adults whose response lasted at least 1 year and 66 children with response of any duration were included. Patients had baseline platelet counts < 30 × 10(9)/L; 95% had ITP of > 6 months in duration. Adults and children each had initial overall response rates of 57% and similar 5-year estimates of persisting response (21% and 26%, respectively). Children did not relapse after 2 years from initial treatment whereas adults did. Initial CR and prolonged B-cell depletion predicted sustained responses whereas prior splenectomy, age, sex, and duration of ITP did not. No novel or substantial long-term clinical toxicity was observed. In summary, 21% to 26% of adults and children with chronic ITP treated with st...Continue Reading

References

Apr 18, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Yossi Cohen, Aaron Polliack
Sep 14, 2002·Annals of the Rheumatic Diseases·M J LeandroG Cambridge
Oct 18, 2002·Blood·Adrian WiestnerGeraldine P Schechter
Oct 18, 2002·Arthritis and Rheumatism·Maria J LeandroDavid A Isenberg
Jan 30, 2003·American Journal of Hematology·Joseph SchwartzJames B Bussel
Feb 1, 2003·Blood·Francesco ZajaGianfranco Ferraccioli
Mar 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·A PestronkT D Levine
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qian GongAndrew C Chan
Feb 4, 2005·The Journal of Pediatrics·Julie WangJames B Bussel
Mar 30, 2005·American Journal of Hematology·Peter BraendstrupHans C Hasselbalch
Mar 22, 2006·The Journal of Experimental Medicine·Megan MacLeodDavid Gray
Mar 22, 2006·Annals of Hematology·Francisco Javier PeñalverUNKNOWN Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP
Aug 18, 2006·European Journal of Pediatrics·Annette Friederike JanssonBernd H Belohradsky
Sep 19, 2006·Best Practice & Research. Clinical Rheumatology·J C W EdwardsM J Leandro
Jan 4, 2007·Annals of Internal Medicine·Donald M ArnoldJohn G Kelton
Sep 18, 2007·Annals of Hematology·Jaime Garcia-ChavezUNKNOWN Mexican Hematology Study Group
Mar 4, 2008·Journal of Thrombosis and Thrombolysis·Semir PasaOrhan Ayyildiz
Mar 6, 2008·British Journal of Haematology·Bernadette Garvey
Aug 16, 2008·Annals of Hematology·Kholood AlasfoorShaker A Mousa
Oct 22, 2008·Pediatric Blood & Cancer·Brigitta U MuellerUNKNOWN Glaser Pediatric Research Network
Sep 5, 2009·American Journal of Hematology·Aisha HasanJames Bussel
Mar 6, 2010·Journal of Clinical Pathology·Lavanya DiwakarAarnoud Huissoon

❮ Previous
Next ❯

Citations

May 25, 2013·International Journal of Hematology·Hirokazu Kashiwagi, Yoshiaki Tomiyama
Dec 18, 2012·The Journal of Clinical Investigation·Matthieu MahévasClaude-Agnès Reynaud
Dec 10, 2013·Hematology·Cindy E Neunert
Mar 13, 2014·International Journal of Hematology·Kousaku MatsubaraMasue Imaizumi
Mar 25, 2014·La Presse médicale·Andrew ShihDonald M Arnold
Mar 19, 2014·La Presse médicale·Bertrand Godeau, Roberto Stasi
Jan 7, 2014·European Journal of Pediatrics·Veerle Labarque, Chris Van Geet
Jul 17, 2015·Expert Review of Clinical Immunology·Thijs W HoffmanGer T Rijkers
Nov 23, 2013·Expert Opinion on Biological Therapy·Saar Gill, David L Porter
Feb 11, 2015·Lancet·Bethan Psaila, Nichola Cooper
May 21, 2013·Expert Opinion on Biological Therapy·Simon HallamAdrian C Newland
Feb 13, 2016·Blood·Jun Peng
Dec 3, 2015·British Journal of Haematology·Maurizio Miano
Mar 7, 2013·The American Journal of the Medical Sciences·Kaelyn H LuDeirdra R Terrell
Nov 6, 2015·British Journal of Haematology·Pamela McKayUNKNOWN British Committee for Standards in Haematology
Oct 7, 2014·Thérapie·Guillaume MoulisMaryse Lapeyre-Mestre
Nov 19, 2013·Pediatric Clinics of North America·David T Teachey, Michele P Lambert
May 30, 2013·Hematology/oncology Clinics of North America·Gaurav Kistangari, Keith R McCrae
Oct 1, 2015·La Revue de médecine interne·S AudiaB Bonnotte
Oct 31, 2012·Pediatric Blood & Cancer·Donald M Arnold
Aug 7, 2012·Journal of Thrombosis and Haemostasis : JTH·S Lakshmanan, A Cuker
Feb 14, 2015·American Journal of Hematology·Michelle Zeller, Donald M Arnold
Sep 17, 2013·European Journal of Haematology·Wilma BarcelliniAlberto Zanella

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.